BACKGROUND: UK tuberculosis (TB) notifications are rising due to disease in the immigrant population. National screening guidelines have been revised but cost-effectiveness analyses are hampered by the lack of data on the comparative performance of tuberculin skin tests (TSTs) and interferon γ release assays (IGRAs) in immigrants. METHODS: Three-way evaluation of TSTs and two IGRAs (QuantiFERON Gold in-tube (QFN-GIT) and T-SPOT.TB) in immigrants aged ≥16 years to quantify test positivity, concordance and factors associated with positivity. Yields were computed at different incidence thresholds and the relative cost-effectiveness of screening was estimated using different latent TB infection (LTBI) screening modalities at varying incidence thresholds with or without port-of-arrival chest x-ray (CXR). RESULTS: 231 immigrants were included; median age 29 (IQR 24-37). TSTs were accepted by 80.9%, read in 93.5% and 30.3% were positive - QFN-GIT and T-SPOT.TB positive in 16.6% and 22.5% respectively. Positive TSTs, QFN-GIT and T-SPOT.TB were independently associated with increasing TB incidence in immigrants' countries of origin (p=0.007, 0.007, 0.037 respectively). Implementing current guidance (threshold 40/100 000 per year) would identify 98-100% of LTBIs (depending on test) but entail testing 97-99% of the cohort; screening at 150/100 000 per year would identify 49-71% of LTBIs but only entail screening half the cohort. The two most cost-effective screening strategies were no port-of-entry chest radiography and screen with single-step QFN-GIT at 250/100 000 per year (incremental cost-effectiveness ratio (ICER)) £21 565.3/case averted); and no port-of-entry CXR and screen with single-step QFN-GIT at 150/100 000 per year (averted additional 7.8 TB cases; ICER £31 867.1/case averted). CONCLUSIONS: UK immigrant screening could cost-effectively and safely eliminate mandatory CXR on arrival by emphasising systematic screening for LTBI with single-step IGRA. Intermediate incidence thresholds balance the need to identify as many imported LTBIs as possible against limited service capacity.
BACKGROUND: UK tuberculosis (TB) notifications are rising due to disease in the immigrant population. National screening guidelines have been revised but cost-effectiveness analyses are hampered by the lack of data on the comparative performance of tuberculin skin tests (TSTs) and interferon γ release assays (IGRAs) in immigrants. METHODS: Three-way evaluation of TSTs and two IGRAs (QuantiFERON Gold in-tube (QFN-GIT) and T-SPOT.TB) in immigrants aged ≥16 years to quantify test positivity, concordance and factors associated with positivity. Yields were computed at different incidence thresholds and the relative cost-effectiveness of screening was estimated using different latent TB infection (LTBI) screening modalities at varying incidence thresholds with or without port-of-arrival chest x-ray (CXR). RESULTS: 231 immigrants were included; median age 29 (IQR 24-37). TSTs were accepted by 80.9%, read in 93.5% and 30.3% were positive - QFN-GIT and T-SPOT.TB positive in 16.6% and 22.5% respectively. Positive TSTs, QFN-GIT and T-SPOT.TB were independently associated with increasing TB incidence in immigrants' countries of origin (p=0.007, 0.007, 0.037 respectively). Implementing current guidance (threshold 40/100 000 per year) would identify 98-100% of LTBIs (depending on test) but entail testing 97-99% of the cohort; screening at 150/100 000 per year would identify 49-71% of LTBIs but only entail screening half the cohort. The two most cost-effective screening strategies were no port-of-entry chest radiography and screen with single-step QFN-GIT at 250/100 000 per year (incremental cost-effectiveness ratio (ICER)) £21 565.3/case averted); and no port-of-entry CXR and screen with single-step QFN-GIT at 150/100 000 per year (averted additional 7.8 TB cases; ICER £31 867.1/case averted). CONCLUSIONS: UK immigrant screening could cost-effectively and safely eliminate mandatory CXR on arrival by emphasising systematic screening for LTBI with single-step IGRA. Intermediate incidence thresholds balance the need to identify as many imported LTBIs as possible against limited service capacity.
Authors: F Marra; C A Marra; M Sadatsafavi; O Morán-Mendoza; V Cook; R K Elwood; M Morshed; R C Brunham; J M Fitzgerald Journal: Int J Tuberc Lung Dis Date: 2008-12 Impact factor: 2.373
Authors: Alasdair R J Bamford; Angela M Crook; Julia E Clark; Zohreh Nademi; Garth Dixon; James Y Paton; Anna Riddell; Francis Drobniewski; Andrew Riordan; Suzanne T Anderson; Amanda Williams; Sam Walters; Beate Kampmann Journal: Arch Dis Child Date: 2009-10-08 Impact factor: 3.791
Authors: Junior Mutsvangwa; Kerry A Millington; Kathryn Chaka; Tafadzwa Mavhudzi; Yin-Bun Cheung; Peter R Mason; Anthony E Butterworth; Elizabeth L Corbett; Ajit Lalvani Journal: Thorax Date: 2010-04 Impact factor: 9.139
Authors: G Orlando; S Merli; L Cordier; F Mazza; G Casazza; A M Villa; L Codecasa; E Negri; A Cargnel; M Ferrarese; G Rizzardini Journal: Infection Date: 2010-04-22 Impact factor: 3.553
Authors: Anil Pooran; Helen Booth; Robert F Miller; Geoff Scott; Motasim Badri; Jim F Huggett; Graham Rook; Alimuddin Zumla; Keertan Dheda Journal: BMC Pulm Med Date: 2010-02-22 Impact factor: 3.317
Authors: Manish Pareek; John P Watson; L Peter Ormerod; Onn Min Kon; Gerrit Woltmann; Peter J White; Ibrahim Abubakar; Ajit Lalvani Journal: Lancet Infect Dis Date: 2011-04-20 Impact factor: 25.071
Authors: Robert W Aldridge; Tom A Yates; Dominik Zenner; Peter J White; Ibrahim Abubakar; Andrew C Hayward Journal: Pathog Glob Health Date: 2015-06 Impact factor: 2.894
Authors: Anna M Mandalakas; H Lester Kirchner; Gerhard Walzl; Robert P Gie; H Simon Schaaf; Mark F Cotton; Harleen M S Grewal; Anneke C Hesseling Journal: Am J Respir Crit Care Med Date: 2015-04-01 Impact factor: 21.405
Authors: P B Shete; D Boccia; P Dhavan; N Gebreselassie; K Lönnroth; S Marks; A Matteelli; D L Posey; M J van der Werf; C A Winston; C Lienhardt Journal: Int J Tuberc Lung Dis Date: 2018-08-01 Impact factor: 2.373
Authors: Aran Singanayagam; Kavina Manalan; Saranya Sridhar; Philip L Molyneaux; David W Connell; Peter M George; Anne Kindelerer; Suranjith Seneviratne; Ajit Lalvani; Melissa Wickremasinghe; Onn Min Kon Journal: Thorax Date: 2013-08-23 Impact factor: 9.139
Authors: Vanessa W Lim; Hwee Lin Wee; Phoebe Lee; Yijun Lin; Yi Roe Tan; Mei Xuan Tan; Lydia Wenxin Lin; Peiling Yap; Cynthia Be Chee; Timothy Barkham; Vernon Lee; Mark Chen; Rick Twee-Hee Ong Journal: BMJ Open Date: 2021-07-15 Impact factor: 2.692
Authors: Matthew K O'Shea; Thomas E Fletcher; Nicholas J Beeching; Martin Dedicoat; David Spence; Helen McShane; Adam F Cunningham; Duncan Wilson Journal: PLoS One Date: 2014-05-09 Impact factor: 3.240